Article info
PDFImmune cell therapies and immune cell engineering
Original research
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
- Correspondence to Dr Nathalie Labarriere; Nathalie.Labarriere{at}univ-nantes.fr
Citation
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
Publication history
- Accepted January 5, 2020
- First published January 29, 2020.
Online issue publication
January 11, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.